Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Meda, through its wholly owned US subsidiary, Meda Pharmaceuticals, has entered into a settlement agreement with Cobalt Pharmaceuticals that resolves the US patent litigation between the companies regarding Cobalt's proposed generic version of Astelin.
Subscribe to our email newsletter
The settlement agreement resolves the patent infringement action filed by Meda after Cobalt’s submission of an abbreviated new drug application (ANDA) to the FDA for a generic version of Astelin in July 2007. Under the settlement agreement, Cobalt admits infringement of Meda’s patent.
The settlement agreement allows Cobalt to launch a generic version of Astelin, under a license from Meda, on August 28, 2010 at the earliest. In such case, Cobalt will pay 32.5% of its net sales of this product to Meda until February 1, 2011.
Astelin is used for treatment of allergic and non-allergic rhinitis. The product is protected in the US by a patent that expires on November 1, 2010, with pediatric exclusivity extending until May 1, 2011.
Anders Lonner, CEO of Meda, said: “With this settlement agreement, Meda has no further patent litigations pending in the US for Astelin.”